^
Association details:
| Biomarker: | CDKN2A negative |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Excerpt:
Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high).
DOI:
10.1093/annonc/mdx344
Trial ID:
Test:
